5AAA

Structure of L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with Crizotinib

Summary for 5AAA

Entry DOI	10.2210/pdb5aaa/pdb
Related	5A9U 5AA8 5AA9 5AAB 5AAC
Descriptor	ALK TYROSINE KINASE RECEPTOR, 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine (3 entities in total)
Functional Keywords	transferase, receptor tyrosine kinase, anaplastic lymphoma kinase, inhibitor, mutant
Biological source	HOMO SAPIENS (HUMAN)
Total number of polymer chains	1
Total formula weight	37393.71
Authors	McTigue, M.,Deng, Y.,Liu, W.,Brooun, A.,Stewart, A. (deposition date: 2015-07-23, release date: 2016-06-08, Last modification date: 2024-01-10)
Primary citation	Shaw, A.T.,Friboulet, L.,Leshchiner, I.,Gainor, J.F.,Bergqvist, S.,Brooun, A.,Burke, B.J.,Deng, Y.,Liu, W.,Dardaei, L.,Frias, R.L.,Schultz, K.R.,Logan, J.,James, L.P.,Smeal, T.,Timofeevski, S.,Katayama, R.,Iafrate, A.J.,Le, L.,Mctigue, M.,Getz, G.,Johnson, T.W.,Engelman, J.A. Resensitization to Crizotinib by the Lorlatinib Alk Resistance Mutation L1198F. N.Engl.J.Med., 374:54-, 2016 Cited by PubMed: 26698910 DOI: 10.1056/NEJMOA1508887 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (1.73 Å)

Structure validation